GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TrivarX Ltd (OTCPK:MDBIF) » Definitions » Gross Profit

MDBIF (TrivarX) Gross Profit : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is TrivarX Gross Profit?

TrivarX's gross profit for the six months ended in Dec. 2024 was $0.00 Mil. TrivarX's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. TrivarX's gross profit for the six months ended in Dec. 2024 was $0.00 Mil. TrivarX's Revenue for the six months ended in Dec. 2024 was $0.00 Mil. Therefore, TrivarX's Gross Margin % for the quarter that ended in Dec. 2024 was N/A%.

TrivarX had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of TrivarX was 97.50%. The lowest was -67.65%. And the median was 38.08%.


TrivarX Gross Profit Historical Data

The historical data trend for TrivarX's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TrivarX Gross Profit Chart

TrivarX Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.05 0.03 0.02 -

TrivarX Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 - - - -

Competitive Comparison of TrivarX's Gross Profit

For the Health Information Services subindustry, TrivarX's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TrivarX's Gross Profit Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, TrivarX's Gross Profit distribution charts can be found below:

* The bar in red indicates where TrivarX's Gross Profit falls into.


;
;

TrivarX Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

TrivarX's Gross Profit for the fiscal year that ended in Jun. 2024 is calculated as

Gross Profit (A: Jun. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

TrivarX's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

TrivarX's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


TrivarX  (OTCPK:MDBIF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

TrivarX had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


TrivarX Gross Profit Related Terms

Thank you for viewing the detailed overview of TrivarX's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


TrivarX Business Description

Traded in Other Exchanges
Address
647 Beaufort Street, Mount Lawley, WA, AUS, 6050
TrivarX Ltd is a health technology company developing AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions. Trivarx's clinical research has enabled the development of cutting-edge proprietary algorithms for spectral analyses of sleep architecture and heart rate variability.

TrivarX Headlines

From GuruFocus

Medibio Submits FDA De Novo Application

By Marketwired Marketwired 07-16-2018

Medibio Receives TGA Approval

By Marketwired Marketwired 06-19-2018

Medibio Launches Global Corporate Mental Health Product

By Marketwired Marketwired 05-01-2018

Medibio Announces Next Tranche of Corporate Health Contracts

By Marketwired Marketwired 05-10-2018

Medibio Provides Market Update

By Marketwired Marketwired 09-10-2018

Medibio Provides Updated Company Presentation

By Marketwired Marketwired 10-05-2018

Receipt of $3,146,835 R&D Tax Incentive Refund

By Marketwired Marketwired 10-15-2018

Medibio Announces Executive Leadership Changes

By Marketwired Marketwired 09-21-2018